Volume 13 Supplement 2

IX Madrid Breast Cancer Conference

Meeting abstracts

IX Madrid Breast Cancer Conference.

Madrid, Spain16-17 November 2011

Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer

Authors: L Pusztai

Citation: Breast Cancer Research 2011 13(Suppl 2):O1

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Molecular classification of triple-negative tumors

Authors: A Prat and CM Perou

Citation: Breast Cancer Research 2011 13(Suppl 2):O2

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?

Authors: R Plummer

Citation: Breast Cancer Research 2011 13(Suppl 2):O3

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Epithelial-mesenchymal transition as a mechanism for the progression of breast carcinoma

Authors: JP Thiery, WJ Sim, K Chua, R Huang, S Mori, T Tan, FC Bidart and JY Pierga

Citation: Breast Cancer Research 2011 13(Suppl 2):O5

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Epigenetics of breast cancer

Authors: M Esteller

Citation: Breast Cancer Research 2011 13(Suppl 2):O6

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Immunity and autoimmunity in breast cancer

Authors: G Curigliano

Citation: Breast Cancer Research 2011 13(Suppl 2):O4

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Insulin resistance in breast cancer: relevance and clinical implications

Authors: PJ Goodwin

Citation: Breast Cancer Research 2011 13(Suppl 2):O7

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
The phosphatidylinositol-3 kinase/mTOR pathway: new agents

Authors: CL Arteaga

Citation: Breast Cancer Research 2011 13(Suppl 2):O8

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
DNA repair and breast cancer: therapeutic opportunities

Authors: DP Silver

Citation: Breast Cancer Research 2011 13(Suppl 2):O9

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
NoncodingRNAs: from bench to bedside

Authors: GA Calin

Citation: Breast Cancer Research 2011 13(Suppl 2):O10

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Targeting HER2 in breast cancer: beyond trastuzumab

Authors: EP Winer

Citation: Breast Cancer Research 2011 13(Suppl 2):O11

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer

Authors: J Baselga, F Costa, H Gomez, C Hudis, B Rapoport, H Roche, LS Schwartzberg, O Petrenciuc, M Shan and WJ Gradishar

Citation: Breast Cancer Research 2011 13(Suppl 2):O12

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Molecular heterogeneity of luminal breast cancer

Authors: S Loi

Citation: Breast Cancer Research 2011 13(Suppl 2):O13

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Translational breast cancer research in luminal breast cancer

Authors: M Dowsett

Citation: Breast Cancer Research 2011 13(Suppl 2):O14

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Interpretation and molecular validation of biomarker studies

Authors: JS Reis-Filho

Citation: Breast Cancer Research 2011 13(Suppl 2):O15

Content type: Oral presentation Published on: 16 November 2011
- View Full Text
- View PDF
Clinical features and prognosis of tubular breast cancer

Authors: M Izquierdo Sanz, F Tresserra Casas, G Nacho Rodríguez, R Fabregas Xaurado, M Cusido Gimferrer, C Ara Perez and S Baulies Caballero

Citation: Breast Cancer Research 2011 13(Suppl 2):P1

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
Abstract withdrawn

Authors:

Citation: Breast Cancer Research 2011 13(Suppl 2):P2

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
Nestin and collagen triple helix repeat containing 1 in breast cancer progression

Authors: G Kharaishvili, D Simkova, M Cizkova, K Bouchalova, G Mgebrishvili, Z Kolar and J Bouchal

Citation: Breast Cancer Research 2011 13(Suppl 2):P3

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy

Authors: L Manso, E Ciruelos, M Codes, J De la Haba, A Galan, J Baena, A Jaen, M Gil, A Murias, I Blancas, E Gonzalez, D Perez, JL Bayo, J Mel, E Garcia-Martinez, R Cubedo…

Citation: Breast Cancer Research 2011 13(Suppl 2):P4

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
Oestrogen receptor status predicts for local recurrence following wide local excision for breast tumours

Authors: JWK Lee, CTM Ong, EY Tan and MYP Chan

Citation: Breast Cancer Research 2011 13(Suppl 2):P5

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value

Authors: E Ciruelos, C Castaneda, T Pascual, E Andrés, HL Gomez, L Manso, N Valdivieso, I Ghanem and H Cortes-Funes

Citation: Breast Cancer Research 2011 13(Suppl 2):P6

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
Lobular carcinoma of the breast: outcome of 205 patients

Authors: E Vega, E Ciruelos, N Valdiviezo, C Mendiola, L Manso, I Ghanem, M Dorta, T Pascual, C Flores and H Cortés-Funes

Citation: Breast Cancer Research 2011 13(Suppl 2):P7

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients

Authors: K Bouchalova, M Cizkova, R Trojanec, V Koudelakova, L Radova, J Furstova, B Melichar, K Cwiertka, G Kharaishvili, Z Kolar and M Hajduch

Citation: Breast Cancer Research 2011 13(Suppl 2):P8

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin

Authors: R Trojanec, V Koudelakova, K Bouchalova, L Radova, H Ondryasova, E Krejci, M Megova, M Cizkova, S Mlcochova, B Melichar and M Hajduch

Citation: Breast Cancer Research 2011 13(Suppl 2):P9

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
microRNA and protein expression in breast cancer formalin-fixed paraffin-embedded samples

Authors: A Gámez-Pozo, I Sánchez-Navarro, CA Castaneda, NI Ferrer, G de Velasco, FG Martínez, E Ciruelos and JÁ Fresno Vara

Citation: Breast Cancer Research 2011 13(Suppl 2):P10

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
Quantitative proteomics reveals novel proteins and central pathways associated with endocrine resistance in breast cancer

Authors: S Løkkegaard, M Bennetzen, D Elias, A Lykkesfeldt, LE Johansen, R Leth-Larsen, JS Andersen and HJ Ditzel

Citation: Breast Cancer Research 2011 13(Suppl 2):P11

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF
The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer

Authors: KH Gravgaard, MB Lyng, A-V Laenkholm, R Søkilde, BS Nielsen, T Litman and HJ Ditzel

Citation: Breast Cancer Research 2011 13(Suppl 2):P12

Content type: Poster presentation Published on: 16 November 2011
- View Full Text
- View PDF

IX Madrid Breast Cancer Conference

Meeting abstracts

Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer

Molecular classification of triple-negative tumors

Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?

Epithelial-mesenchymal transition as a mechanism for the progression of breast carcinoma

Epigenetics of breast cancer

Immunity and autoimmunity in breast cancer

Insulin resistance in breast cancer: relevance and clinical implications

The phosphatidylinositol-3 kinase/mTOR pathway: new agents

DNA repair and breast cancer: therapeutic opportunities

NoncodingRNAs: from bench to bedside

Targeting HER2 in breast cancer: beyond trastuzumab

Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer

Molecular heterogeneity of luminal breast cancer

Translational breast cancer research in luminal breast cancer

Interpretation and molecular validation of biomarker studies

Clinical features and prognosis of tubular breast cancer

Abstract withdrawn

Nestin and collagen triple helix repeat containing 1 in breast cancer progression

Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy

Oestrogen receptor status predicts for local recurrence following wide local excision for breast tumours

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value

Lobular carcinoma of the breast: outcome of 205 patients

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients

Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin

microRNA and protein expression in breast cancer formalin-fixed paraffin-embedded samples

Quantitative proteomics reveals novel proteins and central pathways associated with endocrine resistance in breast cancer

The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer

Follow

Annual Journal Metrics

Breast Cancer Research

Contact us